Tianjin Ringpu Bio-Technology receives new veterinary drug certificates

Tianjin Ringpu Bio-Technology (SZSE:300119) announced that it has obtained new veterinary drug registration certificates from the Ministry of Agriculture and Rural Affairs for two products. The first is a quadruple inactivated vaccine for avian Newcastle disease, avian influenza (H9 subtype), infectious bursal disease, and avian adenovirus disease (group I, type 4). The second is a bivalent egg yolk antibody for duck hepatitis A virus (type 1 + type 3). These certifications will help strengthen the company's core competitiveness and market share in poultry vaccines, while also solidifying its leading position in the field of waterfowl biological products.